Cargando…

Quality of life changes with canakinumab therapy in adults with colchicine resistant FMF

Detalles Bibliográficos
Autores principales:	Gul, A, Özdogan, H, Kasapcopur, O, Erer, B, Ugurlu, S, Sevgi, S, Turgay, S
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4599816/ http://dx.doi.org/10.1186/1546-0096-13-S1-P89

Ejemplares similares

PW01-015 – Canakinumab in adults with colchicin resistant FMF
por: Gül, A, et al.
Publicado: (2013)

Efficacy and safety of canakinumab in adolescents and adults with colchicine-resistant familial Mediterranean fever
por: Gül, Ahmet, et al.
Publicado: (2015)

Epidemiology of colchicine resistant Familial Mediterranean Fever disease (CrFMF) in Turkey
por: Turgay, S, et al.
Publicado: (2015)

PW01-012 – Canakinumab in patients with FMF
por: Ugurlu, S, et al.
Publicado: (2013)

OR7-005 – Canakinumab in childhood colchicine resistant FMF
por: Hashkes, PJ, et al.
Publicado: (2013)

The effect of Anakinra on Quality-of-Life in a family with colchicine-resistant FMF
por: van der Hilst, J, et al.
Publicado: (2015)

How safe it is to treat pregnant FMF patients with Anakinra?
por: Ozdogan, H, et al.
Publicado: (2015)

Development of focal segmental glomerulosclerosis in a patient with Familial Mediterranean Fever resistant to colchicine therapy under treatment with Canakinumab
por: Barut, K, et al.
Publicado: (2015)

The patient experience of Colchicine Resistant-Familial Mediterranean Fever (cr-FMF)
por: Dandekar, P, et al.
Publicado: (2015)

Developing of a new scale for assessing the adherence to colchicine treatment in pediatric patients with FMF
por: Yesilkaya, S, et al.
Publicado: (2015)

Colchicine therapy in children with FMF
por: Knieper, A-M, et al.
Publicado: (2015)

PReS-FINAL-2218: Treatment of colchicines resistant FMF: experience of a pediatric center in Turkey
por: Kara Eroglu, F, et al.
Publicado: (2013)

PReS-FINAL-2204: Developing of a new scale for assessing the adherence to colchicines treatment in pediatric patients with FMF
por: Yesilkaya, S, et al.
Publicado: (2013)

PW01-025 – Definition of colchicine resistance in FMF
por: Demirkaya, E, et al.
Publicado: (2013)

The familial Mediterranean fever (FMF) 50 score: does it work in a controlled clinical trial? Re-analysis of the trial of rilonacept for patients with colchicine resistant or intolerant FMF
por: Hashkes, P, et al.
Publicado: (2015)

Canakinumab therapy in patients with Familial Mediterranean Fever
por: Ugurlu, S, et al.
Publicado: (2015)

Colchicine plus Dapsone in Colchicine‐Resistant FMF Patients
por: Salehzadeh, Farhad, et al.
Publicado: (2019)

Toll like receptor 2 is overexpressed in FMF patients during attacks and inhibited by colchicine treatment
por: Ben-David, H, et al.
Publicado: (2015)

PReS-FINAL-2328: Developing and validating the new severity score for FMF
por: Demirkaya, E, et al.
Publicado: (2013)

PReS-FINAL-2213: Validation of inadequate drug response and definition of colchicum resistance in FMF
por: Demirkaya, E, et al.
Publicado: (2013)

Validity and reliability of medication adherence scale in FMF (adult version)
por: Fidanci, Berna Eren, et al.
Publicado: (2014)

P01-031 – Anakinra for colchicine resistant FMF
por: Ben-Zvi, I, et al.
Publicado: (2013)

Compliance to colchicine treatment and disease activity in Familial Mediterranean Fever (FMF) patients in Middle/Black Sea Region of Turkey (in Çorum region)
por: Karaaslan, Y, et al.
Publicado: (2015)

Factors affecting cardiovascular morbidity in young FMF patients. A comparative analysis in colchicine treated FMF patients with and without cardiovascular disease
por: Roitman, AJ, et al.
Publicado: (2015)

Feasibility of canakinumab withdrawal in colchicine-resistant familial Mediterranean fever
por: Sener, Seher, et al.
Publicado: (2023)

PW01-002 – Colchicine resistant FMF in Turkish children
por: Eroglu, FK Kara, et al.
Publicado: (2013)

Update on the management of colchicine resistant Familial Mediterranean Fever (FMF)
por: El Hasbani, Georges, et al.
Publicado: (2019)

Validity and reliability of medication adherence scale in FMF
por: Fidanci, BE, et al.
Publicado: (2015)

Featuring the phenotype of the FMF prototype
por: Ben-Zvi, I, et al.
Publicado: (2015)

Effectiveness of Canakinumab Treatment in Colchicine Resistant Familial Mediterranean Fever Cases
por: Yücel, Burcu Bozkaya, et al.
Publicado: (2021)

How long is the diagnosis of Familial Mediterranean Fever (FMF) delayed in a region where FMF is common in Turkey?
por: Karaaslan, Y, et al.
Publicado: (2015)

P01-027 – Normal HRV in colchicine-resistant FMF patients
por: Nussinovitch, U, et al.
Publicado: (2013)

P01-015 – Effect of Cochicine on cholesterol in FMF and BS
por: Ugurlu, S, et al.
Publicado: (2013)

P01-011 – Colchicine compliance and amyloidosis
por: Ozdogan, H, et al.
Publicado: (2013)

Canakinumab for the treatment of different refractory autoinflammatory disorders
por: Grein, Ingrid HR, et al.
Publicado: (2014)

PReS-FINAL-2318: The structural and functional changes of biomembrains of FMF and HSP with children
por: Sargsyan, H, et al.
Publicado: (2013)

PReS-FINAL-2220: Cochlear involvement in FMF
por: Keskindemirci, G, et al.
Publicado: (2013)

PReS-FINAL-2221: An earliest diagnosis of FMF
por: Keskindemirci, G, et al.
Publicado: (2013)

Coexistence of PFAPA syndrome and FMF in Armenian children
por: Mkrtchyan, N, et al.
Publicado: (2015)

Effect of interleukin-1 antagonist on growth of children with colchicine resistant or intolerant FMF
por: Pinchevski-Kadir, Shiran, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_3up3i6m20bntfkg41kkglk7t3l